1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Amrutanjan Health Care Limited

Amrutanjan Health Care Limited

497.00
INR
+1.65
(+0.33%)
18.67EPS
29.35P/E
15.83BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
48.49
56.98
63.08
71.36
74.87
86.2
89.22
113.8
138.51
129.63
144.77
155.83
173.53
176.92
Basic EPS, GAAP
4.26
5.1
7.67
7.46
6.83
8.39
8.58
20.94
23
13.65
15.5
17.58
20.03
18.67
Free Cash Flow per Basic Share
5.58
4.28
6.56
1.53
5.49
6.54
5.35
30.43
9.84
3.86
7.3
5.31
-6.58
- -
Dividend per Share
1.75
1.95
3.76
1.4
1.92
1.95
3.15
1.98
4.27
4.94
4.61
4.59
4.57
- -
Book Value per Share
30.53
32.48
33.6
39.59
44.02
49.86
54.54
73.75
90.87
99.65
99.85
113.02
128.11
- -
Tangible Book Value per Share
30.5
32.43
33.52
39.51
43.94
49.71
54.36
73.23
90.07
98.8
99.03
112.42
127.52
- -
Basic Weighted Avg Shares
29
29
29
29
29
29
29
29
29
29
29
29
29
29
Sales/Revenue/Turnover
1,417
1,666
1,844
2,086
2,188
2,520
2,607
3,325
4,045
3,782
4,201
4,505
5,017
5,115
Operating Margin (%)
13.44
12.76
16.19
15.06
12.22
11.72
10.32
23.91
20.26
11.12
11.43
11.89
14.15
11.17
Depreciation Expense
37
32
25
29
31
33
44
37
38
52
61
65
63
67
Net Income, GAAP
124
149
224
218
200
245
251
612
672
398
450
508
579
540
Effective Tax Rate (%)
35.79
38.28
35.14
34.16
39.16
28.92
27.2
25.29
25.82
25.74
27.4
26.47
25.64
25.72
Profit Margin (%)
8.78
8.95
12.16
10.45
9.13
9.73
9.62
18.4
16.61
10.53
10.7
11.28
11.54
10.55
Working Capital
510
570
598
759
890
1,035
868
1,708
1,972
1,969
2,258
2,061
1,655
- -
LT Debt
- -
- -
- -
- -
- -
- -
11
7
3
4
14
17
14
- -
Total Equity
892
950
982
1,157
1,287
1,457
1,594
2,156
2,651
2,908
2,885
3,266
3,702
- -
Return on Invested Capital (%)
12.79
15.31
23.92
22.1
15.39
16.5
13.92
30.21
25.31
11.38
12.02
12.92
13.33
- -
Return on Capital (%)
13.9
15.75
22.68
20
16.24
17.91
16.45
32.57
27.98
14.31
15.5
16.48
16.57
- -
Return on Common Equity (%)
14.51
16.18
23.21
20.38
16.35
17.87
16.44
32.64
27.96
14.33
15.53
16.53
16.62
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
4
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
19,320
14,267
15,835

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,916
- -
Cash, Cash Equivalents & STI
- -
1,705
- -
Accounts Receivable, Net
- -
606
- -
Inventories
- -
374
- -
Total Current Liabilities
- -
1,262
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
4
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.53%
11.69%
13.35%
Free Cash Flow
36.11%
-58.37%
-224.04%
Net Income, GAAP
16.68%
1.79%
13.93%
Sales/Revenue/Turnover
10.9%
8.96%
11.36%
Total Cash Common Dividend
12.33%
24.54%
-0.52%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
837
1,099
1,228
1,354
4,505
2026
940
1,177
1,410
1,498
5,017
2027
1,030
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.6
4.08
6.66
5.25
17.58
2026
2.87
4.83
6.73
5.6
20.03
2027
1.51
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
4.59
2026
- -
- -
- -
- -
4.57
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sambhu Prasad Sivalenka
Full Time Employees
1,260
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No.103 (Old No.42-45), Luz Church Road Chennai TN India 600004
IPO Date
Nov 5, 2009
Website
amrutanjan.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Amrutanjan Health Care Limited manufactures and markets a diverse portfolio of Ayurvedic and allopathic healthcare products focused on pain management, cough and cold relief, women's hygiene, and preventive health beverages; core offerings include flagship Amrutanjan Pain Balm in yellow and white variants, roll-ons such as Faster Relaxation and Period Pain Relief, sprays like Advanced Joint Muscle Spray and Joint Muscular Spray, pain patches including Advanced Pain Relief Patch, Relief Cough Syrup and Cough & Cold ColdRub, Comfy sanitary napkins in Snug Fit Regular Cottony and Slim Fit variants, Fruitnik Electro+ electrolyte drinks in low-sugar and ready-to-drink formats, alongside Stop Pain Dental Gel, Decorn Corn Caps, No Germs Hand Sanitizer, Stop Itch, and Relief Hot Drink. The company operates three state-of-the-art manufacturing units in Tamil Nadu and Telangana, distributes through 1,785 distributors to 1.13 million outlets primarily in India with exports to the Gulf, Africa, Southeast Asia, and other international markets including plans for expanded presence in the US and Europe, and maintains an office in Dubai. Founded in 1893 by Kasinadhuni Nageswara Rao in Mumbai and headquartered at No. 103, Luz Church Road, Mylapore, Chennai, Tamil Nadu, the company shifted its headquarters to Chennai in 1914, became a public limited entity named Amrutanjan Limited in 1936, and changed its name to Amrutanjan Health Care Limited in 2007. Recent developments encompass the launch of its first brick-and-mortar Direct-to-Customer store 'World of Amrutanjan' in Delhi during fiscal 2024 with plans for further expansion, appointment of cricketer Ruturaj Gaikwad as brand ambassador for Electro+, approval in May 2024 for a new manufacturing plant, achievement of Comfy as a ₹1 billion brand, 25% sales growth for Electro+, and sustained high double-digit growth in women's hygiene alongside revenue increases to ₹471.82 crore in gross sales and ₹44.97 crore in profit after tax for fiscal 2024.